GeoVax Labs Business Summary

GeoVax Labs, Inc. (GOVX) is a clinical-stage biotechnology company that generates revenue primarily through federal research grants, government contracts (such as those from the NIH and BARDA), and strategic collaborations, with a long-term business model focused on technology licensing and product commercialization. The company operates through two primary segments: Infectious Disease Vaccines, which leverages its proprietary Modified Vaccinia Ankara (MVA) platform to develop next-generation candidates for COVID-19, Mpox, and hemorrhagic fevers; and Cancer Immunotherapies, centered on its gene-directed therapy Gedeptin® for advanced solid tumors. Direct competitors include Bavarian Nordic, Pfizer, Moderna, and Athira Pharma; GeoVax distinguishes itself by targeting underserved, immunocompromised populations and offering multi-antigenic, durable immune responses that aim to surpass the limitations of first-generation mRNA platforms. The company was co-founded in 2001 by Dr. Harriet Robinson, a renowned pioneer in DNA vaccine technology and current Chief Scientific Officer Emeritus, as a spin-out from Emory University’s Yerkes National Primate Research Center. The executive team is led by Chairman and CEO David A. Dodd, a veteran industry leader with a pedigree of transforming life science firms like Serologicals Corporation and Solvay Pharmaceuticals into multi-billion dollar enterprises. Supporting Dodd are key leaders including Chief Scientific Officer Mark J. Newman, PhD, and Chief Medical Officer Kelly T. McKee, Jr., MD, both of whom possess decades of experience in clinical-stage vaccine development. GeoVax maintains a seasoned board of directors, including Dr. Robert T. McNally and Dr. Jayne Morgan, and is backed by notable institutional investors such as Sabby Management, Armistice Capital, and Renaissance Technologies.